肿瘤细胞治疗研究
英文原题：The Role of Chimeric Antigen Receptor Regulatory T Cells in Promoting Immune Tolerance in Solid Organ Transplantation: Mechanisms and Therapeutic Potential.
The Role of Chimeric Antigen Receptor Regulatory T Cells in Promoting Immune Tolerance in Solid Organ Transplantation: Mechanisms and Therapeutic Potential.
实体器官移植（SOT）是终末期器官衰竭患者的救命手段；然而，需要终身使用免疫抑制剂来预防同种异体移植物排斥反应。
实体器官移植（SOT）是终末期器官衰竭患者的救命手段；然而，需要终身使用免疫抑制剂来预防同种异体移植物排斥反应。这些药物会增加非霍奇金淋巴瘤、肝癌、肾癌和肺癌的风险，并提高对致癌病毒的易感性，包括乙型肝炎病毒和EB病毒。使用嵌合抗原受体（CAR）调节性T（Treg）细胞是一种有前景的方法，可诱导移植耐受，同时尽量减少对免疫抑制剂的依赖。CAR Treg细胞通过减少免疫抑制剂相关的发病率和死亡率，具有提高移植物存活率和生活质量的潜力。尽管在移植耐受方面取得了显著进展，但由于对Treg生物学的理解有限以及技术障碍，挑战依然存在。本综述讨论了免疫抑制的影响、CAR和CAR Treg生物学、Treg介导耐受的机制、CAR Treg制造、临床试验、优化策略，以及CAR Treg基于细胞疗法在SOT中现有的挑战和未来方向。
Solid organ transplantation (SOT) is a life-saving procedure for patients with end-stage organ failure; however, lifelong immunosuppressant use is needed to prevent allograft rejection. These drugs increase the risk of non-Hodgkin lymphoma, liver, kidney, and lung cancers, and heighten susceptibility to oncogenic viruses, including hepatitis B and Epstein-Barr virus. The usage of chimeric antigen receptor (CAR) regulatory T (Treg) cells is a promising approach to induce transplant tolerance while minimizing dependence on immunosuppressants. The CAR Tregs offer the potential to enhance graft survival and quality of life by reducing immunosuppressant-related morbidity and mortality. Despite remarkable progress in transplantation tolerance, challenges remain owing to a limited understanding of Treg biology and technical barriers. This review discusses the implications of immunosuppression, CAR and CAR Treg biology, mechanisms of Treg-mediated tolerance, CAR Treg manufacturing, clinical trials, optimization strategies, and existing challenges and future directions for CAR Treg-based therapies in SOT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
